Advertisements

Viprosal B

Quick links to important sections

Viprosal B

Selected form

Advertisements
Advertisements

Treatment option: Myositis

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Viprosal B

Property Description
Active Ingredient Viper Venom, Camphor, Sodium Salicylate, Turpentine Oil
Form Ointment
Pharmacological Class Topical Rubefacient and Analgesic Agent
Common Use Symptomatic relief of muscle and joint pain
Origin Combination of natural derivatives and a synthetic compound

What is the Medicinal Classification of Viprosal B?

Viprosal B is a non-prescription medicinal preparation, formally classified as a Topical Rubefacient and Analgesic Agent. This designation indicates its primary function is to ease discomfort through external application, which is achieved by stimulating local blood flow (rubefaction) and providing localized pain relief. The product is consistently presented as an Ointment, a semisolid dosage form specifically intended for external/topical use. This structure facilitates sustained contact and absorption of the active components on the skin, firmly establishing it as a combination product with multiple active substances.

What is Viprosal B Ointment Made Of?

The therapeutic effect of the ointment is derived from a blend of four distinct active ingredients: Viper Venom (from the European Adder, Vipera berus), Racemic Camphor, Turpentine Oil, and Sodium Salicylate. This preparation has a hybrid origin/type, incorporating powerful natural derivatives like the viper venom and turpentine oil with the synthetic compound Sodium Salicylate. Camphor is included as a rubefacient for its local skin-stimulating effect. The viper venom component is a key differentiating factor, indicating a traditional approach to pain relief not commonly found in singular salicylate preparations.

What is the General Purpose of Viprosal B?

The general purpose of Viprosal B is to provide targeted, symptomatic comfort for general muscle and joint aches by initiating a powerful local response. The preparation delivers a synergistic mechanism: the counter-irritant effect from the Viper Venom and Camphor helps to distract the user from deeper pain signals, while the Turpentine Oil and Camphor induce a noticeable warming effect that temporarily increases localized blood circulation. This mechanism, combined with the mild anti-inflammatory support associated with the topical salicylate component, serves the therapeutic goal of alleviating general musculoskeletal pain and stiffness.

Advertisements

What side effects are possible with Viprosal B?

Possible Side Effects and Safety Information

The safety profile for Viprosal B Ointment, as documented in official regulatory sources, is primarily characterized by local reactions due to its topical application and counter-irritant properties. These reactions are classified within Skin and Subcutaneous Tissue Disorders.


Official Adverse Reaction Profile

Classification Common Reactions Serious Reactions (Rare Risk)
System-Organ Class Skin and Subcutaneous Tissue Disorders Immune System Disorders
Observed Effects Redness (Erythema), Itching (Pruritus), Burning sensation, and local dermatitis are frequently noted. Hypersensitivity reactions, which may rarely include severe manifestations like angioedema or extensive exfoliative dermatitis, are documented as potential risks.

Local effects, such as the intended warming or burning sensation, are typically expected to occur shortly after application. The frequency of most specific reactions is often classified as Not Known in regulatory monographs, although local irritation is frequent.


Population-Specific and Use Restrictions

Safety documents specify several limitations on the use of this ointment:

  • Contraindications include known hypersensitivity to any component (Viper Venom, Camphor, Sodium Salicylate, or Turpentine Oil).
  • The product must not be applied to damaged, broken, or ulcerated skin (e.g., open wounds).
  • Use is contraindicated in children under 11 years of age due to safety concerns primarily related to the Camphor component.
  • Caution is advised in individuals with severe hepatic or renal impairment and during pregnancy or lactation due to the theoretical risk of systemic salicylate absorption.

These constraints define the official boundaries for safe use and structure the medicine's risk profile.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Viprosal B overdose focuses on the potential for systemic toxicity resulting from accidental ingestion of the ointment or excessive topical use over large areas of the skin. Due to the presence of salicylate and camphor components, this exposure can lead to severe complications.

Documented Manifestations

System Clinical Signs
Salicylism Tinnitus, hyperpnoea (rapid breathing), lethargy, vomiting, and dizziness.
Neurological Severe overdose can lead to seizures, tremors, and loss of consciousness, particularly linked to camphor toxicity.

Emergency Actions and High-Risk Situations

Immediate medical attention is required if the product is swallowed or if an overdose is suspected. Official guidance mandates that users must seek immediate medical help or contact a Poison Control Center right away under these circumstances.

Management of toxicity is defined as symptomatic and supportive treatment. This may include fluid administration and the use of sodium bicarbonate to manage systemic salicylate effects. There is no specific chemical antidote listed in regulatory documents for the product's primary toxic components.

Special populations carry specific warnings: The risk of Reye's syndrome exists for children and teenagers with viral illnesses (varicella or influenza) who use salicylate-containing products. Patients with existing hepatic or renal impairment are also noted as having an increased risk of systemic toxicity.

Advertisements

Therapeutic Uses of Viprosal B

What Viprosal B treats: main uses and benefits

Viprosal B is a topical medicine used for the symptomatic relief of pain associated with various musculoskeletal conditions. The therapeutic domains for which this medicine is commonly applied include managing discomfort associated with articular pain, neuritis, neuralgia, lumbago, myalgia, and radiculitis. Patients often use this external preparation in scenarios such as managing localized discomfort from strains, sprains, or muscle pain following physical activity, or chronic pain associated with conditions like certain forms of arthritis.

The benefit for the patient involves achieving the temporary reduction of mild to moderate localized pain, which may support greater comfort during daily activities. The product's intended action is to provide support for the relief of muscle and joint pain.

Quick Fact: Relief for Muscle Aches and Joint Discomfort

Regulatory References

  1. Health Canada Health Product InfoWatch
Advertisements

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Viprosal B

The eligibility for Viprosal B Ointment is strictly defined by regulatory documents, focusing on patient status and clinical contraindications. The medicine is primarily intended for use by adults who do not have any specific restricting conditions.


Absolute Contraindications

Use is formally contraindicated in patients with a history of cerebral and coronary circulation abnormalities, severe hepatic impairment, or severe renal impairment. Individuals with a known hypersensitivity to any of the active substances (Viper Venom, Camphor, Sodium Salicylate, Turpentine Oil) must also not use the ointment. Additionally, the medicine must not be applied to ulcerated, damaged, or diseased skin or near mucous membranes.


Restrictions by Age and Physiological State

Official labeling states that the medicine is not recommended for children or adolescents due to insufficient safety and efficacy data. Likewise, Viprosal B should not be used by pregnant women or breastfeeding women as safety has not been established in these physiological states. These restrictions are mandated by national health authorities to define the appropriate population for its use.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The officially documented interaction profile for Viprosal B, a topical medicine, is primarily defined by the systemic risks associated with its Sodium Salicylate component, rather than specific metabolic enzyme interactions.

Pharmacodynamic Interaction Risk

The co-administration of this product with other medicinal products containing salicylates or Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including both topical and oral formulations, is associated with a risk of additive systemic effects. This pharmacodynamic interaction may increase the potential for systemic toxicity, such as effects on blood coagulation, which is a key regulatory caution.

Exposure-Dependent Constraints

The potential for a systemic drug interaction is subject to specific constraints regarding the application site. Regulatory documents explicitly state that application to ulcerated or broken skin or over extensive body surface areas increases the systemic absorption of active components. This condition-dependent exposure modification directly heightens the likelihood and severity of any potential systemic interaction.

Population-Specific Interaction Notes

Interaction-related risks are considered more significant in specific patient populations. The product's regulatory caution notes that reduced drug clearance in cases of severe hepatic impairment or severe renal impairment can lead to higher systemic accumulation of the absorbed salicylate, thereby increasing the clinical relevance of potential drug interactions.

Contraindicated Combinations: No specific medicinal product is formally listed as a contraindicated drug-drug combination based on interaction risk.

Advertisements

Mechanism of Action

How Viprosal B Works — Mechanism of Action


Modulating Peripheral Sensory Input via Ion Channels

The initial physiological change arises from the action of Camphor, which first activates and then rapidly desensitizes the Transient Receptor Potential Vanilloid 1 (TRPV1) ion channel on peripheral sensory neurons, reducing the capacity for sustained nociceptive signal transmission. This peripheral signal gating is reinforced by the Turpentine Oil and Viper Venom components, which stimulate local nerve endings to create a competing signal that modulates afferent sensory input.


Localized Hyperemia and Vascular Reflex

A parallel mechanism involves the action of the rubefacient components that chemically stimulate local sensory nerve endings. This action triggers a reflex and the localized release of vasoactive mediators, causing the vasodilation of small blood vessels near the skin surface. This physiological change induces hyperemia (increased local blood flow), which is associated with a localized increase in tissue temperature and may facilitate the local distribution of other active components due to increased microcirculation.


Interference with Inflammatory Mediator Synthesis

The formula includes Sodium Salicylate, which modulates the physiological response by acting as an inhibitor of Cyclooxygenase (COX) enzymes. By interfering with this pathway, the synthesis of pro-inflammatory mediators, such as certain prostaglandins, is reduced in the local tissue. This mechanism interferes with the pathway that promotes localized inflammatory signaling and modulates the sensitization of peripheral nerve endings.

Advertisements

Dosage and Administration Information

Administration Scope

Feature Guideline
Route of administration Topical (for external application)
Dosing schedule Apply a small amount, quantified as a stripe of 5 to 10 cm of the ointment, directly to the painful area.
Timing in relation to meals (if applicable) Not applicable; intended for external use only.
Preparation requirements (if applicable) No preparation steps (e.g., dilution or reconstitution) are specified for the ready-to-use ointment.
Age-group administration rules Not recommended for use in children and adolescents (specifically under 11 years of age) as specific data for these populations are limited.
Missed-dose rules If a dose is missed, apply it as soon as possible, unless the next scheduled application is imminent. A double dose should not be used to compensate for the missed use.
Special procedural conditions Before the initial use, a skin sensitivity test on a limited skin area is used to verify local tolerability.

Instruction Classifications (High-Level)

Classification Pattern
Administration method type Topical (Ointment applied directly to the skin).
Frequency pattern As-needed / Daily, applied once or twice per day, with frequency adjusted based on the individual's condition.
Basis of use Derived from the documented guidelines for the product.
Use-context constraints The total duration of application is variable and determined by the nature and severity of the condition being addressed.

Resulting Procedural Structure

Standardized step sequence:

  • Step 1: Conduct a skin sensitivity test on a small area prior to the first full application.
  • Step 2: Measure the application amount, which is a stripe of ointment between 5 cm and 10 cm in length.
  • Step 3: Apply the measured ointment directly to the affected area and massage the ointment into the skin until absorbed.
  • Step 4: Repeat application once or twice per day, ensuring the next application is not a double dose to compensate for a missed use.

Connection to the overall use protocol:

The instructions establish the use of Viprosal B as a topical, external administration procedure defined by specific, measurable limits. This protocol includes a standardized dosing amount (5 to 10 cm stripe) and a maximum frequency of twice daily, linking the application count to the individual condition. These steps structure the treatment course, which remains variable in total duration based on the condition, without crossing into safety or therapeutic claims.

Advertisements

Recent Clinical Evidence

Viprosal B: Recent Clinical Evidence

Clinical studies have investigated the application of Viprosal B ointment in the management of pain, particularly in the context of joint and neurological conditions.

Research Focus on Osteoarthritis

One area of clinical investigation has been the use of Viprosal B in the complex treatment regimen for patients with osteoarthritis of the knee (gonarthrosis) at early stages (first and second stages). A comparative study observed the pain reduction outcomes in patients who received local applications of Viprosal B ointment alongside systemic treatment (nonsteroidal anti-inflammatory drugs) versus those who received only the systemic treatment.

  • Observed Tendency: The study noted a better tendency for pain reduction in the group that included local applications of the ointment in their therapeutic regimen.
  • Study Conclusion: This research suggested that local applications of Viprosal B in the complex therapy for early-stage osteoarthritis may contribute to improving treatment efficiency.

Safety and Tolerability Profile

Research has generally described the local application of Viprosal B as well-tolerated in the context of the studies conducted. Specific studies on its use in the complex therapy of knee osteoarthritis reported that the addition of Viprosal B did not result in local or systemic side effects in the study participants. However, regulatory information often notes potential local skin reactions due to known excipients, such as contact dermatitis.

Indications and Unaddressed Populations

Clinical trials have primarily focused on adults experiencing neuralgic and joint pain. Due to a lack of specific data, the product is not recommended for use in children and adolescents. No interaction studies have been formally conducted regarding its use with other medicines.

Key Studies & References

  1. Topical preparations containing viper venom: a systematic review of clinical evidence for musculoskeletal pain.
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Viprosal B (FAQ)


Q: Can I use Viprosal B if I have sensitive skin?

Official regulatory guidance includes the instruction that a skin sensitivity test should be performed on a small skin area before the first full application to help verify local tolerability. Additionally, official product information notes that the ointment contains cetostearyl alcohol, which may be associated with causing local skin reactions like contact dermatitis.


Q: Can Viprosal B interact with blood pressure medicine?

The documented interaction risk for Viprosal B is primarily related to the potential for additive systemic effects if it is combined with other topical or oral products containing salicylates or NSAIDs. This potential for systemic effects is noted to be increased if the ointment is applied to large areas or broken skin.


Q: What should I do if I accidentally swallow a small amount of Viprosal B?

Viprosal B is strictly for external topical use and is not intended to be swallowed. In the event of accidental ingestion, regulatory guidance indicates that medical assistance should be sought.


Q: Can Viprosal B cause skin redness?

Yes, official safety information lists redness (erythema) as an observed adverse effect. This redness is a localized reaction, which is associated with the product’s action of stimulating local blood flow.


Q: Can Viprosal B be used on open wounds or broken skin?

No, regulatory documents state that the ointment is contraindicated and must not be applied to damaged, broken, or ulcerated skin. It should only be applied to intact skin.


Q: Are there known contraindications for people with kidney issues using Viprosal B?

Yes, official regulatory documents state that use is formally contraindicated in patients with severe renal impairment (severe kidney issues). This restriction is in place due to the theoretical risk of systemic accumulation of the absorbed salicylate component.


Q: Is there a risk of systemic absorption with Viprosal B?

Regulatory documents note that the application of the ointment to ulcerated or broken skin or over extensive body surface areas increases the potential for systemic absorption of the active components.


Q: What happens if I use Viprosal B for longer than recommended on the label?

The total duration of application is variable and determined by the specific condition being addressed. However, using any topical product for a prolonged time or over large areas increases the risk of local skin reactions and systemic absorption.


Q: Why is Viprosal B sometimes called a counter-irritant?

The mechanism of Viprosal B is consistent with a counter-irritant action. This action occurs because components like Camphor and Viper Venom work to stimulate the skin locally, creating a sensation that modulates the perception of deeper pain.


Q: Can Viprosal B be used on the face or neck area?

Regulatory documents advise against application near mucous membranes and on damaged or diseased skin. The ointment should only be applied to the specific painful area of the body as described in the official labeling.


Q: Can athletes use Viprosal B before or after exercise?

The product’s purpose is for the symptomatic comfort of muscle and joint aches. The maximum application frequency is set at once or twice per day and should be adjusted based on the individual’s condition.


Q: Are there any known issues with using Viprosal B while pregnant?

Viprosal B should not be used by pregnant or breastfeeding women. The restriction is in place because the safety of the medicine has not been established in these physiological states.


Q: What ingredients cause the warming feeling in Viprosal B?

The warming effect is primarily induced by the actions of Turpentine Oil and Camphor. These components stimulate local sensory nerve endings, which triggers a localized increase in blood flow and creates the perception of warmth.


Q: Can I cover the area with a bandage after applying Viprosal B?

Regulatory documents advise that covering the application area with occlusion (such as an airtight or restrictive dressing) increases the risk of systemic absorption of the active components.


Q: How does Viprosal B differ from other topical pain relief products?

The key differentiating factor is its status as a combination product that contains Viper Venom (from the European Adder), alongside other agents like Camphor, Turpentine Oil, and Sodium Salicylate.


Q: Does Viprosal B have any steroids in it?

No, the active ingredients listed on the official product information—Viper Venom, Camphor, Sodium Salicylate, and Turpentine Oil—do not include any corticosteroid or steroid compounds.


Q: Can Viprosal B be used for chronic pain conditions?

Clinical studies have investigated the product’s use for conditions like osteoarthritis, which can be chronic. The total duration of treatment is variable and should be determined based on the nature and severity of the condition being addressed.


Q: Are there research studies available on the long-term use of Viprosal B?

Official regulatory documents cite studies for specific conditions, but they do not contain specific research data to define or support long-term use of the product.


Q: Does Viprosal B have a strong smell?

Yes, official product descriptions indicate that the ointment has a noticeable odor characteristic of the active components, specifically a camphor and turpentine smell.


Q: Is Viprosal B suitable for treating nerve pain?

Clinical studies have investigated the product’s application in the management of neuralgic conditions. Its action, which modulates peripheral sensory input, may be relevant for discomfort associated with neuralgic conditions.


Q: Does Viprosal B expire?

Yes, as a medicinal product, Viprosal B is legally required to have an expiry date printed on the original packaging by the manufacturer to ensure its potency and stability.


Q: What if Viprosal B gets into my eye?

The product is strictly contraindicated for use near mucous membranes. Regulatory guidance advises immediately washing the area thoroughly and seeking professional medical assistance in the event of contact with the eyes.


Q: Can Viprosal B be used alongside heating pads or ice packs?

The product is designed to create a powerful warming effect and applying external heat sources alongside the ointment could contribute to increased local irritation or discomfort.


Q: What are the non-drug components in Viprosal B?

The non-drug components, also known as excipients, found in the ointment include white petrolatum, cetostearyl alcohol, solid paraffin, sodium cetostearyl sulfate, glycerol, sodium chloride, and purified water.


Q: Is Viprosal B considered a narcotic?

No, the product is classified as a Topical Rubefacient and Analgesic Agent. Its active ingredients do not include any substances that are classified as narcotics or controlled substances.


Q: Is Viprosal B a prescription-only medicine in some countries?

Based on the regulatory documents provided, the product is formally classified as a non-prescription medicinal preparation.


Q: Does Viprosal B contain capsaicin?

No, the official list of active ingredients is Viper Venom, Camphor, Sodium Salicylate, and Turpentine Oil. Capsaicin is not listed as a component.


Q: Can Viprosal B be used for a knee sprain?

The product is used for symptomatic comfort related to general muscle and joint aches, including post-traumatic pain. The product’s general purpose aligns with providing symptomatic relief for common musculoskeletal discomfort.


Advertisements

How should Viprosal B be stored and disposed of?

How to Store and Dispose of Viprosal B?

Viprosal B ointment must be stored under specific temperature control to maintain its stability. The product is required to be kept below 25°C (Do not store above 25 C). The medicine must not be refrigerated or frozen.

The ointment should remain in its original package and must be stored in a location that is out of the sight and reach of children.


Disposal Instructions

Expired or unused Viprosal B must not be disposed of via wastewater (such as pouring down the sink) or household waste. This regulatory instruction is in place to help protect the environment. Patients are required to consult a pharmacist for guidance on the proper procedure for discarding unused medicine.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Viprosal B found in:

A-Z Index: